Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao, Gerald P Linette, Luc Thomas, Paul Lorigan, Kenneth F Grossmann, Jessica C Hassel, Michele Maio, Mario Sznol, Paolo A Ascierto, Peter Mohr, Bartosz ChmielowskiAlan Bryce, Inge M Svane, Jean-Jacques Grob, Angela M Krackhardt, Christine Horak, Alexandre Lambert, Arvin S Yang, James Larkin
Dive into the research topics of 'Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial'. Together they form a unique fingerprint.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science